NRG Therapeutics Limited
- Biotech or pharma, therapeutic R&D
Advancing a pipeline of first-in-class, CNS-penetrant oral small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with the aim of restoring mitochondrial function and slowing or halting the progression of Parkinson’s and ALS.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}